ResMed's Q2 2026 earnings: Sleep apnea gadgets 'disrupt' market, investors still wide awake with doubt

ResMed Inc. reported its Q2 2026 earnings, providing insight into the company's performance. On the earnings call, ResMed's management discussed the company's financial results, highlighting revenue growth and profitability. As of the second quarter of 2026, ResMed has demonstrated its ability to adapt to the evolving healthcare landscape, driven by its portfolio of sleep and respiratory care products. The company's strong financial position is attributed to its strategic investments in digital health technologies and its expanding customer base. With a global presence, ResMed operates in over 140 countries, serving a large customer base. The earnings call transcript reveals the company's commitment to innovation, with a focus on developing new products and services to address the growing demand for healthcare solutions. ResMed's Q2 2026 earnings report underscores the company's position as a leader in the medical technology industry, with a market capitalization of over $30 billion.